Skip to main content
. 2020 Jun;22(6):748–756. doi: 10.1016/j.jmoldx.2020.02.010

Table 3.

Effect of DNA Pretreatment on Background Error in KRAS and GNAS Hotspot Mutations in Plasma Samples

Case Study group DNA treatment Mutation hotspot dNGS score
G12A G12C G12D G12V G12R G12S G13D R201C R201H Overall dNGS score
2 Healthy control None
UNG
0 0
0 0
1 0
0 0
0 0
0 0
0 0
0 0
0
1
1
1
3 Healthy control None
UNG
0 0
0 0
0 1
1 0
0 3
0 0
2 5
0 2
2
0
13
3
4 Healthy control None
UNG
0 0
0 0
0 0
1 0
0 0
0 0
0 0
0 1
1
0
1
2
17 Disease control None
PreCR + UNG
0 0
0 0
3 5
1 1
0 0
0 0
1 0
0 1
0
0
9
3
18 Disease control None
PreCR + UNG
0 0
0 0
0 3
0 2
0 0
0 0
1 2
0 0
0
0
6
2
33 Disease control None
PreCR + UNG
0 0
0 0
0 1
0 1
0 0
0 1
0 0
0 0
1
0
2
2
68 PDAC None
PreCR + UNG
0 0
0 0
0 2
0 0
0 0
0 0
0 0
0 0
0
0
2
0
121 PDAC None
PreCR + UNG
0 0
0 0
2 3
0 1
0 0
0 0
0 0
0 0
1
1
6
2

The mean number of positive wells calculated for untreated samples was 5 compared with 1.9 for pretreated DNA samples (P = 0.047).

dNGS, digital next-generation sequencing; PDAC, pancreatic ductal adenocarcinoma; UNG, uracil N-glycosylase.